July 27, 2018 09:45 AM EDTUpdated 10:06 AM

In for the China biotech gold rush, BeiGene eyes monster $800M-plus Hong Kong IPO

Amber Tong

Fast on the heels of Ascletis’ record $400 million raise on the Hong Kong stock exchange, BeiGene is proposing its own IPO in the city …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Big leases, bigger regrets: Biotech slump turns swanky offices from asset into liability

Altos Labs buys anti-aging startup Dorian Therapeutics

Genentech expands deal with molecular glue biotech Orionis for $105M upfront

Cocaine vaccine, a longshot attempt to quell cravings, yields mixed data in small study

Updated: Trump administration reveals 'most favored nation' drug price country targets

sponsored

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?